Drug class

Proteasome inhibitors clinical trials

A class of medicines: the studies that test any of its 10 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Proteasome Inhibitors.

studies test it: 957
open now: 61
in phase 3: 86
first study started: 1999

Get an email when these change. Save the proteasome inhibitors studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Medicines in this class

Studies that test each. A study of two counts under both, and once above.

Bortezomib: 651
Carfilzomib: 157
Ixazomib: 125
Marizomib: 11
ONX 0912: 7
KZR-616: 6
Delanzomib: 3
Proteasome Inhibitor TQB3602: 2
Proteasome Inhibitor SHY-ONC6: 1
M3258: 1

Studies by the year they started

949 studies that test it; most in 2006 (70)

Studies that test Proteasome inhibitors, by start year
Year	Studies
1999	2
2000	3
2001	18
2002	13
2003	20
2004	42
2005	64
2006	70
2007	46
2008	50
2009	46
2010	56
2011	44
2012	41
2013	57
2014	54
2015	49
2016	38
2017	35
2018	35
2019	40
2020	30
2021	21
2022	22
2023	19
2024	14
2025	5
2026	15

By phase

A phase 1/2 study counts in both.

Early Phase 1: 9
Phase 1: 338
Phase 2: 631
Phase 3: 86
Phase 4: 24
No phase: 15

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Multiple Myeloma: 413
Lymphoma, Mantle-Cell: 36
Precursor Cell Lymphoblastic Leukemia-Lymphoma: 23
Waldenstrom Macroglobulinemia: 21
Leukemia, Myeloid, Acute: 20
Lymphoma: 20
Lymphoma, Non-Hodgkin: 18
Carcinoma, Non-Small-Cell Lung: 17
Lymphoma, Large B-Cell, Diffuse: 14
Immunoglobulin Light-chain Amyloidosis: 14
Leukemia: 10
Lymphoma, Follicular: 10

Who runs them

Industry 176 · Other 781

National Cancer Institute (NCI) (80) · M.D. Anderson Cancer Center (43) · Millennium Pharmaceuticals, Inc. (43) · Amgen (30) · Mayo Clinic (26) · Memorial Sloan Kettering Cancer Center (20) · Dana-Farber Cancer Institute (19) · University of Arkansas (17)

Studies

Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing one of them · 957

See all 957 studies that test one of the proteasome inhibitors →

Codes

What other systems call Proteasome inhibitors · ClinicalTrials.gg INT008955

MeSH (NLM) D061988Proteasome InhibitorsOne source ClinicalTrials.gov

System	Code	Name there	Checked by
MeSH (NLM)	D061988	Proteasome Inhibitors	One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.